CoChat

The GLP‐1 receptor agonist liraglutide protects against oxidized LDL‐induced endothelial inflammation and dysfunction via KLF2

Open access
Yue, Wen, Li, Yi, Ou, Dengke, Yang, Qing · 2019 · IUBMB Life
Cited by 60

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Cardiovascular complications are the major causes of the mortality and morbidities in diabetic patients. The diabetic patients have an increased risk of developing atherosclerosis, which could lead to heart attack and stroke. Glucagon‐like peptide 1 (GLP‐1) receptor agonists are a class of potent anti‐glycemic agents to treat diabetes. Recently, several GLP‐1 receptor agonists have been found to have cardiovascular benefit independent of their glucose lowing ability. Liraglutide is one of clinically approved effective GLP‐1 receptor agonists. In this study, we explored the molecular mechanism of Liraglutide against oxidized low‐density lipoprotein (ox‐LDL) in cultured endothelial cells. Our data show that Liraglutide treatment ameliorates ox‐LDL caused reduction of the transcriptional factor KLF2. In the same experiment, Liraglutide also rescues ox‐LDL induced reduction of mitogen‐activated protein kinase (MAPK) kinase extracellular signal regulated kinase 5 (ERK5) phosphorylation, and blockage of ERK5 activity by its inhibitor XMD8‐92 abolishes the protection of Liraglutide on KLF2 expression. These facts suggest that the action of Liraglutide on endothelial KLF2 is dependent on ERK5. Liraglutide also recovers ox‐LDL caused reduction of endothelial tight junctions protein Occludin and ameliorates ox‐LDL induced endothelial monolayer permeability increase. On the other hand, Liraglutide inhibits ox‐LDL induced expression of vascular adhesion molecules (E‐selectin and vascular cell adhesion molecule 1), and prevents ox‐LDL induced attachment of monocytes adhesion to endothelial cells. Moreover, Liraglutide mitigates ox‐LDL triggered reduction of endothelial nitric oxide synthase (eNOS) expression and NO release. Collectively, our study provides multiple facets of the mechanisms that Liraglutide is a protective agent in endothelial cells and has the potential implication in therapeutic usage of vascular complication in diabetes patients. © 2019 IUBMB Life, 71(9):1347–1354, 2019

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/iub.2046

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 60

Metadata

Authors
Yue, W., Li, Y., Ou, D., & Yang, Q.
Venue
IUBMB Life
Publisher
Wiley
Published
2019-04-10
Volume
71
Issue
9
Pages
1347-1354
ISSN
  • 1521-6543 (ISSN-L)
  • 1521-6551
OpenAlex
W2938775788
Cited by
60
References
9
FWCI
3.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The GLP‐1 receptor agonist liraglutide protects against oxidized LDL‐induced endothelial inflammation and dysfunction via KLF2. https://app.cochat.ai/papers/10.1002/iub.2046
The paper
Yue, W., Li, Y., Ou, D., & Yang, Q. (2019). The GLP‐1 receptor agonist liraglutide protects against oxidized LDL‐induced endothelial inflammation and dysfunction via KLF2. IUBMB Life. https://doi.org/10.1002/iub.2046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.